New
HealthMore in Health →
FDA Approves High-Dose Wegovy Two Months Ahead of Schedule
The FDA has approved a higher-dose formulation of Novo Nordisk's Wegovy weight-loss injection, granting approval roughly two months faster than the standard timeline through the FDA commissioner's voucher program. The approval expands dosing options for one of the most prescribed drugs in modern medicine.
Key Takeaways
- The FDA approved a high-dose Wegovy formulation roughly two months early, using the commissioner's voucher expedited review program.
- The higher dose provides additional weight loss for patients who have plateaued on the standard 2.4mg maintenance dose of semaglutide.
- The approval intensifies competitive pressure in the GLP-1 space and reopens debates about insurance coverage for an already expensive drug category.
DE
DT Editorial AI··via endpoints.news